Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2-subgroup using diffuse optical tomography

被引：0

作者：

Altoe, Mirella L. ^{[1
]}

Marone, Alessandro ^{[1
]}

Kim, Hyun K. ^{[1
,2
]}

Guo, Hua ^{[3
]}

Hibshoosh, Haninna ^{[3
]}

Tejada, Mariella ^{[4
]}

Crew, Katherine D. ^{[4
,5
]}

Accordino, Melissa K. ^{[4
]}

Trivedi, Meghna S. ^{[4
]}

Kalinsky, Kevin ^{[4
]}

Hershman, Dawn L. ^{[4
,5
]}

Hielscher, Andreas H. ^{[1
]}

机构：

[1] NYU, Tandon Sch Engn, Dept Biomed Engn, Brooklyn, NY 11201 USA

[2] Columbia Univ, Dept Radiol, Irving Med Ctr, New York, NY 10032 USA

[3] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10032 USA

[4] Columbia Univ, Dept Med, Irving Med Ctr, Div Hematol Oncol, New York, NY 10032 USA

[5] Columbia Univ, Dept Epidemiol, Irving Med Ctr, New York, NY 10032 USA

来源：

MULTISCALE IMAGING AND SPECTROSCOPY III | 2022年 / 11944卷

关键词：

Difuse optical tomography; deoxy-hemoglobin; breast cancer; neoadjuvant chemotherapy; pCR; molecular subtype; HR+/HER2-;

D O I：

10.1117/12.2609729

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS)during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 +/- 0.22) as compared to patients with a non-pCR (1.14 +/- 0.24, P <.005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.

引用

页数：4

共 50 条

[41] Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy
Altoe, Mirella L.
Marone, Alessandro
Kim, Hyun K.
Kalinsky, Kevin
Hershman, Dawn L.
Hielscher, Andreas H.
Ha, Richard S.
BIOMEDICAL OPTICS EXPRESS, 2019, 10 (08) : 4305 - 4315
[42] Distinct early proliferation response to neoadjuvant anti-HER2 antibody drug conjugate ± endocrine therapy in early breast cancer in the WSG ADAPT HER2+/HR+ trial
Gluz, Oleg
Nitz, Ulrike
Sherko, Kuemmel
Stefan, Kraemer
Braun, Michael
Schumacher, Claudia
Aktas, Bahriye
Forstbauer, Helmut
Reimer, Toralf
Fasching, Peter
Potenberg, Jochem
Hofmann, Daniel
Kates, Ronald E.
Wuerstlein, Rachel
Christgen, Matthias
Kreipe, Hans H.
Harbeck, Nadia
CANCER RESEARCH, 2015, 75
[43] Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes
Altoe, Mirella L.
Kalinsky, Kevin
Marone, Alessandro
Kim, Hyun K.
Guo, Hua
Hibshoosh, Hanina
Tejada, Mariella
Crew, Katherine D.
Accordino, Melissa K.
Trivedi, Meghna S.
Hershman, Dawn L.
Hielscher, Andreas H.
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1949 - 1957
[44] Does chemotherapy benefit patients with HR+/HER2-invasive lobular breast cancer?
Yaghi, Marita
Jabbal, Iktej
Bilani, Nadeem
Zerdan, Maroun Bou
Elson, Leah
Li, Hong
Saravia, Diana
Stone, Elizabeth
Nahleh, Zeina
CANCER RESEARCH, 2022, 82 (04)
[45] Real-world treatment of HER2+and HR+/HER2-early breast cancer in county areas of China
Ji, Y.
Wang, J.
Dai, G.
Zhou, F.
Meng, Q.
Wu, Q.
Qu, H.
Liu, H.
Liu, M.
Tian, Y.
Tan, X.
He, W.
Qin, Z.
Tang, H.
Luo, G.
Liu, Y.
Ren, Y.
Luo, J.
Wang, M.
Lu, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1474 - S1474
[46] Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer
不详
ONCOLOGIST, 2021, 26 : S7 - S8
[47] PREDICTING OPTIMAL TREATMENT REGIMENS FOR HR+/HER2-BREAST CANCER BASED ON ELECTRONIC HEALTH RECORDS USING RANDOM FOREST
Cui, Z.
Kadziola, Z.
Faries, D. E.
Lipkovich, I
Ratitch, B.
Li, X.
Sheffield, K.
Carter, Cuyun G.
VALUE IN HEALTH, 2020, 23 : S8 - S9
[48] A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2-breast cancer-FINEST study
Chen, Li
Wu, Wen-Ya
Liang, Fei
Liu, Guang-Yu
Yu, Ke-Da
Wu, Jiong
Di, Gen-Hong
Fan, Lei
Wang, Zhong-Hua
Li, Jun-Jie
Shao, Zhi-Ming
CANCER COMMUNICATIONS, 2025,
[49] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
Luciana de Moura Leite
Marcelle Goldner Cesca
Monique Celeste Tavares
Debora Maciel Santana
Erick Figueiredo Saldanha
Paula Tavares Guimarães
Daniella Dias Silva Sá
Maria Fernanda Evangelista Simões
Rafael Lima Viana
Francisca Giselle Rocha
Simone Klog Loose
Sinara Figueiredo Silva
Rafaela Pirolli
Camilla Albina Zanco Fogassa
Bruna Raphaeli Silva Mattos
Fernando Augusto Batista Campos
Solange Moraes Sanches
Vladmir Cláudio Cordeiro de Lima
Noam Falbel Pondé
Breast Cancer Research and Treatment, 2021, 190 : 155 - 163
[50] HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
de Moura Leite, Luciana
Cesca, Marcelle Goldner
Tavares, Monique Celeste
Santana, Debora Maciel
Saldanha, Erick Figueiredo
Guimaraes, Paula Tavares
Sa, Daniella Dias Silva
Simoes, Maria Fernanda Evangelista
Viana, Rafael Lima
Rocha, Francisca Giselle
Loose, Simone Klog
Silva, Sinara Figueiredo
Pirolli, Rafaela
Fogassa, Camilla Albina Zanco
Mattos, Bruna Raphaeli Silva
Campos, Fernando Augusto Batista
Sanches, Solange Moraes
de Lima, Vladmir Claudio Cordeiro
Ponde, Noam Falbel
BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 155 - 163

← 1 2 3 4 5 →